AN2 Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed May 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 13, 2025

ANTX$4.000.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Cash Flows

(in thousands)

	Three Months EndedMarch 31,
	2025	2024
Cash flows used in operating activities
Net loss	$(10,649)	$(16,617)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	2,047	2,385
Net accretion of discount on investments	(443)	(1,091)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	645	1,109
Accounts payable	(244)	(243)
Accrued compensation	(1,147)	(3,023)
Accrued liabilities	(411)	233
Other current liabilities	(422)	(346)
Net cash used in operating activities	(10,624)	(17,593)
Cash flows from investing activities
Purchases of investments	(22,307)	—
Maturities of investments	31,500	26,290
Net cash provided by investing activities	9,193	26,290
Cash flows from financing activities
Proceeds from issuance of common stock under the ESPP	38	124
Proceeds from exercise of stock options	27	225
Net cash provided by financing activities	65	349
Net (decrease) increase in cash and cash equivalents	(1,366)	9,046
Cash and cash equivalents at the beginning of the period	21,351	15,647
Cash and cash equivalents at the end of the period	$19,985	$24,693

AN2 Therapeutics, Inc.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.